Pfizer's CFO has resigned, according to news that was reportedly submitted Sunday night. Could there be any connection to Peter Rost's reports (based on former Pfizer employee Ashok Idnani's documents and allegations)? Mike Zubillaga's (of "Buckets of Money" fame) boss at AstraZeneca has also resigned.
Pfizer has been developing a potential blockbuster of an HIV treatment: Miraviroc, the first three syllables of whose name suggest (Mirabile) nothing short of miraculous. Resistance to HIV treatments is becoming a serious problem and news of the drug was extremely welcome to HIV patients, their families and the rest...
While IT talks about Web 3.0, we poor mortals in the publishing business are still struggling with Web 2.0, but Peter Rost's Question Authority, Pharmalot and Pharmagossip all report that AstraZeneca's CEO is ready to investigate illicit sales and marketing practices stemming from the "Buckets of Money" scandal.
Peter Rost posted an update on the A-Z sales and marketing saga on his blog. Apparently, AZ reps were given PPT summarizing clinical trial results (from tests that couldn't be directly comparable) of AZ's vs. competitors' drugs. Provided "as background" and "FYI" (wink wink).
AstraZeneca's official response. ASTRAZENECA AND ITS EMPLOYEES COMMITTED TO HIGHEST STANDARDS OF ETHICS AND INTEGRITY April 13, 2007"”Wilmington, Delaware"”AstraZeneca (NYSE: AZN) is presently the focus of news stories that began when senior management became aware of the contents of an unauthorized newsletter.
Need more reasons to celebrate the fact that you chose a career in the pharma industry other than sales? If results of public opinion polls aren't enough to convince you, just look at what has been happening at AstraZeneca since Peter Rost made public the "buckets of money" comment that...
Taking a break from Easter egg coloring, Spring cleaning, etc. , just learned that the AstraZeneca sales rep who approached each oncologist office visit envisioning "buckets of money" has been dismissed. This seems extremely hypocritical of the company.